Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer
Our findings point to the negative impact of KRAS mutations, particularly G12C and G12V, on RC treatment outcomes. Adaptive resistance by upregulation of ERBB genes limits the efficacy of KRAS inhibitors. Combining these with pan-ERBB inhibitors enhances anti-tumor effects in patient-derived cellular RC models, showing its potential as an alternative to the combination with anti-EGFR antibodies.
Authors
- Constanza Tapia Contreras (ORCID: https://orcid.org/0000-0003-2054-0963)
- Hanna Zimmermann (ORCID: https://orcid.org/0000-0002-1476-3477)
- Michael B. Ghadimi (ORCID: https://orcid.org/0000-0001-8208-1526)
- Matthias Wirth (ORCID: https://orcid.org/0000-0002-8340-0872)
- Jochen Gaedcke (ORCID: https://orcid.org/0000-0002-6130-5874)
- Michael Linnebacher (ORCID: https://orcid.org/0000-0001-8054-1402)
- Felix Rühlmann
- Melanie Spitzner (ORCID: https://orcid.org/0000-0002-3673-0625)
- Jonas Buchloh
- Marian Grade
- Carolin Schneider (ORCID: https://orcid.org/0000-0003-3539-9026)
- Stefan Küffer (ORCID: https://orcid.org/0000-0001-8443-601X)
- Günter Schneider (ORCID: https://orcid.org/0000-0003-1840-4508)
- Xin Fang (ORCID: https://orcid.org/0000-0003-2098-6623)
- Lena Conradi
- Tiago de Oliveria
Institutions
- Humboldt-Universität zu Berlin (DE)
- Städtisches Klinikum Karlsruhe (DE)
- Universitätsmedizin Göttingen (DE)
- Institute of Clinical Cancer Research (DE)
- University of Rostock (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- United European Gastroenterology Journal
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1002/ueg2.70086
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Deutsche Forschungsgemeinschaft